No photo of Seema Singhal

View Scopus Profile

Seema Singhal

  • 15009 Citations
1990 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Myeloma, Transplantation

Certifications and Licenses

Internal Medicine

Training Experience

1991Residency, Bombay University, India
1992Fellowship, Hadassah University Hospital, Israel

Education/Academic qualification

MD, Bombay University

… → 1991

Research interests

  • Amyloidosis
  • Monoclonal Antibodies
  • Multiple Myeloma
  • Plasma Cell Disorders
  • Stem Cell Transplant
  • Waldenstroms

Fingerprint Dive into the research topics where Seema Singhal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #213304: Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Singhal, S.

Quintiles, Inc., GlaxoSmithKline LLC

3/11/20 → 3/11/23

Project: Research project

Prot #68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)

Singhal, S.

Janssen Research & Development, LLC

2/11/20 → 2/11/23

Project: Research project

Prot #CC-92480-MM-002: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory

Singhal, S.

Celgene Corporation

11/14/19 → 11/14/22

Project: Research project

Prot #CC-220-MM-001: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 Monotherapy and in Combination with Other Treatments in Sub

Singhal, S.

ICON Clinical Research, LLC, Celgene Corporation

10/10/19 → 10/10/22

Project: Research project

Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

Singhal, S.

Merck Sharp & Dohme Corp.

1/26/17 → 1/26/20

Project: Research project

Research Output

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., Singhal, S., Pawlish, K., Peters, E. S., Bock, C., Mohrbacher, A., Stram, A., Berndt, S. I., Blot, W. J., Casey, G., Stevens, V. L. & 50 others, Kittles, R., Goodman, P. J., Diver, W. R., Hennis, A., Nemesure, B., Klein, E. A., Rybicki, B. A., Stanford, J. L., Witte, J. S., Signorello, L., John, E. M., Bernstein, L., Stroup, A. M., Stephens, O. W., Zangari, M., Van Rhee, F., Olshan, A., Zheng, W., Hu, J. J., Ziegler, R., Nyante, S. J., Ingles, S. A., Press, M. F., Carpten, J. D., Chanock, S. J., Mehta, J., Colditz, G. A., Wolf, J., Martin, T. G., Tomasson, M., Fiala, M. A., Terebelo, H., Janakiraman, N., Kolonel, L., Anderson, K. C., Le Marchand, L., Auclair, D., Chiu, B. C. H., Ziv, E., Stram, D., Vij, R., Bernal-Mizrachi, L., Morgan, G. J., Zonder, J. A., Huff, C. A., Lonial, S., Orlowski, R. Z., Conti, D. V., Haiman, C. A. & Cozen, W., Jan 14 2020, In : Blood Advances. 4, 1, p. 181-190 10 p.

Research output: Contribution to journal › Article

Open Access

    • Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

    Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E. & 11 others, Martin, T., Omel, J., Raje, N., Sborov, D., Singhal, S., Stockerl-Goldstein, K., Tan, C., Weber, D., Johnson-Chilla, A., Keller, J. & Kumar, R., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 10, p. 1154-1165 12 p.

    Research output: Contribution to journal › Review article

    Open Access
    • 4 Scopus citations

    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    KEYNOTE-183 Investigators, Sep 2019, In : The Lancet Haematology. 6, 9, p. e459-e469

    Research output: Contribution to journal › Article

    • 22 Scopus citations

    Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

    Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan-Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

    Research output: Contribution to journal › Article

    • 6 Scopus citations

    Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines

    Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kang, Y., Kassim, A., Liedtke, M., Malek, E., Martin, T. & 10 others, Neppalli, V. T., Omel, J., Raje, N., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Weber, D., Yahalom, J., Kumar, R. & Shead, D. A., Jan 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 1, p. 11-20 10 p.

    Research output: Contribution to journal › Review article

    • 54 Scopus citations